Hangzhou Tigermed Consulting Co., Ltd (3347.HK) Stock Price, News, Quote & History - Yahoo Finance
HKSE - Delayed Quote HKD

Hangzhou Tigermed Consulting Co., Ltd (3347.HK)

35.100 -1.250 (-3.44%)
At close: 4:08 PM GMT+8
Loading Chart for 3347.HK
DELL
  • Previous Close 36.350
  • Open 36.350
  • Bid 35.100 x --
  • Ask 35.250 x --
  • Day's Range 34.900 - 37.150
  • 52 Week Range 22.100 - 65.900
  • Volume 1,187,600
  • Avg. Volume 2,562,982
  • Market Cap (intraday) 49.325B
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) 16.71
  • EPS (TTM) 2.100
  • Earnings Date Apr 25, 2024
  • Forward Dividend & Yield 0.62 (1.69%)
  • Ex-Dividend Date May 25, 2023
  • 1y Target Est 69.29

Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

www.tigermedgrp.com

9,701

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 3347.HK

Performance Overview: 3347.HK

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

3347.HK
0.71%
SSE Composite Index
6.02%

1-Year Return

3347.HK
48.69%
SSE Composite Index
4.16%

3-Year Return

3347.HK
75.83%
SSE Composite Index
9.64%

5-Year Return

3347.HK
70.50%
SSE Composite Index
5.96%

Compare To: 3347.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3347.HK

Valuation Measures

Annual
As of 5/16/2024
  • Market Cap

    51.01B

  • Enterprise Value

    46.90B

  • Trailing P/E

    17.26

  • Forward P/E

    17.83

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.03

  • Price/Book (mrq)

    1.38

  • Enterprise Value/Revenue

    6.00

  • Enterprise Value/EBITDA

    17.21

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.36%

  • Return on Assets (ttm)

    3.45%

  • Return on Equity (ttm)

    7.92%

  • Revenue (ttm)

    7.24B

  • Net Income Avi to Common (ttm)

    1.69B

  • Diluted EPS (ttm)

    2.100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.45B

  • Total Debt/Equity (mrq)

    14.87%

  • Levered Free Cash Flow (ttm)

    247.26M

Research Analysis: 3347.HK

Analyst Price Targets

33.38
69.29 Average
35.100 Current
239.91 High
 

Earnings

Consensus EPS
 

Company Insights: 3347.HK

People Also Watch